STOCK TITAN

Aprea Therapeutics (APRE) awards RSUs and stock options to director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aprea Therapeutics director Bernd R. Seizinger reported equity awards that increase his stake in the company. He received 3,135 restricted stock units granted on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, as long as he continues serving on the board. He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. After these grants, he directly holds 48,910 common shares.

Positive

  • None.

Negative

  • None.
Insider Seizinger Bernd R.
Role Director
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 12,555 $0.00 $0.00
Grant/Award Common Stock 3,135 $0.00 $0.00
Holdings After Transaction: Stock Options (Right to Buy) — 12,555 shares (Direct); Common Stock — 48,910 shares (Direct)
Footnotes (2)
  1. F1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
  2. F2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
RSUs granted 3,135 units Restricted stock units granted June 16, 2026
Options granted 12,555 options Stock options granted June 16, 2026
Option exercise price $0.7293 per share Stock options on common stock
Shares held after 48,910 shares Common stock directly owned after grants
Vesting date June 16, 2027 RSUs and options vesting date
Option expiration June 16, 2036 Expiration date of stock options
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of $0.7293 per share"
vest financial
"which will vest and be settled in common stock on June 16, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"The option vests in full on June 16, 2027 and has an expiration date of June 16, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Aprea Therapeutics (APRE) director Bernd Seizinger report on this Form 4?

He reported receiving new equity awards. These include restricted stock units and stock options granted as part of his director compensation at Aprea Therapeutics, increasing his direct common stock holdings.

How many restricted stock units did Bernd Seizinger receive from Aprea Therapeutics (APRE)?

He received 3,135 restricted stock units. These RSUs were granted on June 16, 2026 and will vest and settle in common stock on June 16, 2027, subject to his continued service on the board.

What stock options were granted to Bernd Seizinger by Aprea Therapeutics (APRE)?

He was granted options covering 12,555 shares of common stock. The options have a $0.7293 per share exercise price, vest in full on June 16, 2027, and carry an expiration date of June 16, 2036.

When do Bernd Seizinger’s Aprea Therapeutics (APRE) RSUs and options vest?

Both awards are scheduled to vest on June 16, 2027. The 3,135 restricted stock units will settle in common stock, and the 12,555 stock options will become fully exercisable on that same vesting date.

How many Aprea Therapeutics (APRE) shares does Bernd Seizinger hold after these grants?

Following the equity awards, he directly holds 48,910 shares of Aprea Therapeutics common stock. This figure reflects his ownership immediately after the June 16, 2026 grants reported in the Form 4.

What conditions apply to Bernd Seizinger’s Aprea Therapeutics (APRE) equity awards?

Both the RSUs and options require continued board service through June 16, 2027. The filing notes vesting is subject to his continued service and mentions possible acceleration under certain conditions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Seizinger Bernd R.

(Last)(First)(Middle)
3805 OLD EASTON ROAD

(Street)
DOYLESTOWN PENNSYLVANIA 18902

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026A3,135(1)A$0.0048,910D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$0.729306/16/2026A12,555 (2)06/16/2036Common Stock12,555$0.0012,555D
Explanation of Responses:
1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
/s/ John Hamill, as Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)